They agreed that T-DXd could be considered in the second-line setting in endocrine-refractory patients with HR-positive/HER2-low breast cancer who have received at least one prior line of chemotherapy in the metastatic setting or whose disease recurred during or within 6 months of completing adjuvant chemotherapy. The gene discussed is ERBB2; the disease is breast cancer.